和元生物(688238.SH)2025年度归母净亏损2.21亿元

Core Viewpoint - The company reported a revenue of 268 million yuan for the fiscal year 2025, reflecting a year-on-year growth of 7.86%, but also recorded a net loss attributable to shareholders of 221 million yuan [1] Group 1: Financial Performance - The company achieved an operating revenue of 268 million yuan, which is a 7.86% increase compared to the same period last year [1] - The net loss attributable to the parent company's shareholders was 221 million yuan during the reporting period [1] Group 2: Industry Context - The domestic biopharmaceutical sector is characterized by both opportunities and challenges, showcasing a complex landscape of diversified development and intense market competition [1] - The company remains focused on its core business in cell and gene therapy CRO/CDMO, leveraging national and industry development policies to strategically position itself in the regenerative medicine application field [1] Group 3: Operational Strategy - The company emphasized strengthening customer resource reserves, enhancing brand influence, and promoting industry development during the reporting period [1] - The main performance goals include improving internal capabilities, upgrading operational management, and driving cost reduction and efficiency enhancement to lay a solid foundation for future business development [1]